Psoriatic therapeutics and glucose-6-phosphate dehydrogenase.
The inhibitory effects of various agents on the enzyme glucose-6-phosphate dehydrogenase have been studied in vitro. Stress is laid on the calculation of kinetic parameters such as true K-I values. The most active inhibitor was methotrexate, closely followed by cGMP. The increase in inhibitory activity after incubation of methotrexate with liver slices is discussed.
D000818:Animals; D001623:Betamethasone / Q000494:pharmacology; D002417:Cattle; D006152:Cyclic GMP / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D005492:Folic Acid / Q000494:pharmacology; D005954:Glucosephosphate Dehydrogenase / Q000037:antagonists & inhibitors*; D006168:Guinea Pigs; D007700:Kinetics; D008727:Methotrexate / Q000494:pharmacology; D011565:Psoriasis / Q000188:drug therapy* / Q000201:enzymology
D005492:Folic Acid; D001623:Betamethasone; D005954:Glucosephosphate Dehydrogenase; D006152:Cyclic GMP; D008727:Methotrexate